AI assistant
Sending…
ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2024
Mar 27, 2024
35331_dirs_2024-03-27_b3259c17-7597-494e-a313-fb011fd69ff9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2024-03-25
Reporting Person: Gilliland Robertson H. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-25 | Stock Option (Right to Buy) | $1.35 | A | 12000 | Acquired | 2034-03-24 | Common Stock (12000) | Direct |
Footnotes
F1: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.
More from ADIAL PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 11
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Feb 24
Capital/Financing Update
2026
Feb 4
Board/Management Information
2026
Jan 6
Proxy Solicitation & Information Statement
2026
Jan 6
Proxy Solicitation & Information Statement
2025
Dec 23
Capital/Financing Update
2025
Dec 19
Regulatory Filings
2025
Dec 18
Capital/Financing Update
2025
Dec 12